Related AMGNSocial Media Beat: What The Crowd & Experts Think Of Oil, Biotech & LinkedInStocks Hitting 52-Week HighsAre You Ready For A Pullback BIIB AMGN GILD CELG UTHR JAZZ GOOG FB NFLX APA APC EOG PANW DO RIG(Marketfy Insights)Related CELG5 Biotechs With Catalysts Coming This WeekIs More M&A On The Way For Large-Cap Biotechs?Are You Ready For A Pullback BIIB […]
Market Rallies on FED comments but Biotechs are Left Behind
FED Expected to Raise Rates as Labor Market Tightens
The FED stands pat on rates but is on track to raise rates later this year, possibly at the September meeting, as jobs are on track but inflation is still not above 2%. The market began rally at 2P EDT after the FED […]
By Johanna BennettDo you want safe, or sexy?That’s the question facing biotechnology investors, according to a recent research note from Cowen analysts that previews the sector’s second-quarter financial results.“In heady times, large cap provides a safe haven, smid caps the sex appeal,” reads the note.After shrugging off a selloff in late June, the Nasdaq Biotechnology index has gained 30% since […]
Markets are rebounding today after a horrible beginning to the week. Looking in the biotech sector, I’m seeing a sea of green with very few blemishes. I’ve also been able to dig out a few great opportunities in the sector. Here they are…Gilead Sciences Is Likely To See Long Run GainsGilead Sciences, Inc. (NASDAQ: GILD)I’ve talked about Gilead Sciences quite […]
By Ben LevisohnUBS analyst Mathhew Roden and team still like biotech stocks, but think it’s time to get more selective, recommending “high quality risk reward names” like Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX), while downgrading Amgen (AMGN) and Regeneron Pharmaceuticals (REGN). They explain why:
Freya Ingrid Morales/Bloomberg News
Although we still think that biotech will continue to outperform the broader markets […]
This maddening sideways chop continues and the best “risk on” sector, biotech, looks heavy and tired. The leaders in this space are heavy, AMGN has a bearish head and shoulder pattern going on and CELG and BIIB just cant stop stepping on their feet. GILD acts the best of the big four biotechs. The other biggie, REGN, continues to hang […]
By Ben LevisohnBarclays’ Geoff Meacham and Jonathan Eckard are feeling good about biotech stocks like Biogen (BIIB) and Alexion Pharmaceuticals (ALXN) heading into the summer. They explain why:
Associated Press
[The] Nasdaq Biotech Index index has outperformed the broader market eight out of 10 times over the summer period (Memorial Day to Labor Day) and in 2Q/3Q, there are a number of meaningful […]
Earnings season in the biotech sector started on a positive note with Amgen (AMGN – Analyst Report) reporting better-than-expected first quarter 2015 results. Meanwhile, The Medicines Co. (MDCO – Analyst Report) received some good news with an FDA advisory panel backing its antiplatelet agent. However, companies like Athersys (ATHX – Snapshot Report) and Ampio suffered setbacks on the pipeline front.Recap […]
Some biotech stocks are puking all over themselves and others act like drunks walking in traffic. The IBB has found a home at its 50 day moving average which coincides with its daily uptrend line.This is a huge spot for support and if it breaks lower it could do a quick cascade to the 100 moving average which is down […]
GILD Stock Continues Recovery From Monday’s FallGilead Sciences, Inc. (NASDAQ: GILD)GILD stocks fell hard Monday; losing more than two percent as the company issued a warning to doctors treating their patients with Sovaldi in combination with antiarrhythmics. However, the slide stopped and the stock started to move in the positive direction. Today, it seems as though the stock is staying […]
